





Blood 142 (2023) 3002-3004

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

621.LYMPHOMAS: TRANSLATIONAL-MOLECULAR AND GENETIC

Highly Sensitive Interleukin Score for Intra-Ocular Lymphoma Diagnosis: Evidence from Analysis of 5-Year Real-Life of Use

Elise Sourdeau¹, Martin Chevalier², Hélène Masse³, Julie Gueudry⁴, Yann Maucourant⁵, Marie-Laure Le Lez⁶, Philippe Gohier⁷, Marie Alice Laville⁸, Nathalie Cassoux, MDPhD⁹, Fatma Abid Mzid¹⁰, Mohamed Ali Gargouri¹¹, Marie Marechal¹², Guido Ahle¹³, Clotilde Devin¹⁴, Sara Touhami², Valerie Touitou¹⁵, Caroline Houillier¹⁶, Khe Hoang-Xuan, MDPhD 17, Choquet Sylvain 18, Carole Soussain, MD 19, Adélaïde Toutee 2, Magali Le Garff-Tavernier 14

- ¹ Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Pitie-Salpetriere Hospital, Paris, FRA
- ²Ophtalmology Department, Assistance Publique-Hôpitaux de Paris, Pitie-Salpetriere Hospital, Paris, France
- ³Ophtalmology Department, Centre Hospitalo-Universitaire de Nantes, Nantes, France
- ⁴Ophtalmology Department, Centre Hospitalo-Universitaire de Rouen, Rouen, France
- ⁵Ophtalmology Department, Centre Hospitalo-Universitaire de Rennes, Rennes, France
- ⁶Ophtalmology Department, Centre Hospitalier Régional Universitaire de Tours, Tours, France
- ⁷Ophtalmology Department, Centre Hospitalo-Universitaire d'Angers, Angers, France
- ⁸ Ophtalmology Department, Centre Hospitalo-Universitaire de Caen, Caen, France
- ⁹Ophtalmology Department, Institut Curie, Université de Paris Cité, Paris, FRA
- ¹⁰Ophtalmology Department, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris, France
- ¹¹Ophtalmology Department, Fondation ophtalmologique Adolphe de Rothschild, Paris, France
- ¹²Ophtalmology Department, Hôpital d'Instruction des Armées Percy, Clamart, France
- ¹³Neurology Department, Hôpitaux Civils de Colmar, Colmar, France
- ¹⁴Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Pitie-Salpetriere Hospital, Paris, France
- ¹⁵AP-HP, HôPital Pitié-salpêtrièRe, Paris, FRA
- ¹⁶Neuro-Oncology Department, Assistance Publique des Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, FRA
- ¹⁷Neuro Oncology Department, Assistance Publique-Hôpitaux de Paris, Pitie-Salpetriere Hospital, Paris, FRA
- ¹⁸ Hopital de la Pitié Salpetrière, APHP, Paris, FRA
- ¹⁹ Hôpital René Huguenin Institut Curie, Saint-Cloud, FRA

Introduction

Primary vitreoretinal lymphoma (PVRL) is a rare and aggressive subset of large B-cell lymphoma of immune-privileged sites. It can occur independently or concomitantly to primary central nervous system lymphoma. Symptoms are not specific and can easily be confused with other uveitis. Diagnosis of intra-ocular lymphoma (IOL), including PVRL and secondary lymphoma localization, is based on malignant lymphoid cells identification in vitrectomy(cytology, flow cytometry, molecular analysis). Nevertheless, the fragility of lymphoma cells and low cellularity of samples make diagnosis difficult with these cellular tools. The quantification of interleukin (IL) in intraocular fluids is a promising soluble alternative approach. Based on IL-10 and IL-6 levels, an Interleukine Score for intra-Ocular Lymphoma Diagnosis (ISOLD) designed for aqueous humor (AH) and vitreous was published to guide the diagnosis of IOL (Costopoulos et al, Ophtalmology, 2016). The aim of this work was to evaluate ISOLD performances in real-life practice after five-year of use in a hospital laboratory.

Material and methods

IL-10 and IL-6 were measured in intra-ocular sample in a single laboratory using the cytometric bead array® kit (BD Biosciences TM) on a FACS Canto II cytometer, with a limit of quantification of 2.5 pg/ml. ISOLD is calculated at diagnosis in AH (AH-ISOLD) or vitreous (V-ISOLD) samples and is associated with a probability of having a large B-cell IOL. This score classifies patients according to two groups: i) reliable zone: ISOLD < -4.6 (<1% probability to have IOL) and ISOLD > +4.6 (>99% probability to have IOL); ii) doubtful zone: ISOLD ranging from -4.6 to +4.6 for which the probability and the clinical context have to be considered. All calculated ISOLD from January 2017 to December 2021 were collected. Centers with more than 30 intraocular samples with a calculated ISOLD were contacted to retrieve patients' definitive diagnosis and potential treatments.

Results

POSTER ABSTRACTS Session 621

During these 5 years, IL-10 and IL-6 levels have been quantified for 2796 intraocular samples from 70 centers. ISOLD was calculated at diagnosis for 2013 ocular samples. Clinical data were obtained for 1449 samples (1220 AH and 229 vitreous) corresponding to 1243 patients from 13 out of the 18 centers contacted. 9.7% of patients had an IOL, 82.2% had another diagnosis than IOL and 8.1% of patients had no established diagnosis (Figure 1). Considering the 1341 samples with an established diagnosis, 92.7% were in the reliable zone and 7.3% were in the doubtful zone. For the 1128 AH samples, 1050 AH-ISOLD (93.1%) were in the reliable interpretation zone, with a concordant result for 98.6% of them (n=1035 samples) and a discordant result for 1.4% of them (n=15) (Table 1). The sensitivity and specificity were respectively estimated at 90.6% and 99.3% with a positive predictive value (PPV) of 91.7% and a negative predictive value (NPV) of 99.2%. Seventy-eight AH-ISOLD were in doubtful zone including 23 LIO and 55 others diagnoses than IOL. For the 213 vitreous samples, 193 V-ISOLD (90.6%) were in the reliable interpretation zone, with a concordant result for 98.4% of them (n=190 samples) and a discordant result for 1.6% of them (n=3) (Table 1). The sensitivity and specificity were estimated at 97.6% and 99.1%, respectively with a PPV of 98.8% and a NPV of 98.2%. Twenty V-ISOLD were in doubtful zone including 5 LIO and 15 others diagnoses than IOL. Three patients of the 8 who had a false-negative AH-ISOLD had a positive V-ISOLD. For the 17 AH-ISOLD in the doubtful zone, 4 of them had a V-ISOLD concordant with the diagnosis and 2 had an AH-ISOLD in the other eye concordant with the diagnosis. Independently of the sample type, the main cause of false-negative results was administration of corticosteroids prior to sampling and the main causes of false-positive results were infectious diseases (varicella and herpes virus, toxoplasmosis, syphilis).

Conclusion

This study confirmed on a 5-year period of real life practice that ISOLD, based on IL-10 and IL-6 levels, is a powerful tool to guide the diagnosis towards IOL. In more than 90% of intra-ocular samples, ISOLD was in reliable interpretation zone with very high sensitivity and specificity levels. In case of positive or doubtful AH-ISOLD, a vitrectomy is needed to make the diagnosis. Easy to use, not expansive, this score appears very useful to optimize the diagnostic approach of this rare and aggressive large B-cell lymphoma.

Disclosures Ahle: Abbvie: Honoraria; Novartis: Honoraria; Roche: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria. Le Garff-Tavernier: Alexion: Consultancy, Honoraria; Janssen: Honoraria; Novartis: Honoraria.

https://doi.org/10.1182/blood-2023-182192




Table 1. Diagnosis according to ISOLD compared to clinical diagnosis (n samples)

	Diagnosis according to ISOLD Clinical diagnosis	Possible no-IOL ISOLD < -4.6 Probability > 99%	Probable no-IOL -4.6 < ISOLD < 0 Probability 50-99%	Probable IOL 0 < ISOLD < +4.6 Probability 50-99%	Possible IOL ISOLD > +4.6 Probability > 99%	Total
Aqueous	IOL	8	3	20	77	108
	no-IOL	958	38	17	7	1020
	Total	966	41	37	84	1128
Vitreous	IOL	2	1	4	82	89
	no-IOL	108	14	1	1	124
	Total	110	15	5	83	213